Results of a prospective randomized, open-label, noninferiority study of tbo-filgrastim (Granix) versus filgrastim (Neupogen) in combination with plerixafor for autologous stem cell mobilization in patients with multiple myeloma and non-hodgkin lymphoma
Biology of Blood and Marrow Transplantation Sep 18, 2017
Bhamidipati PK, et al. - For stem cell mobilization in patients with multiple myeloma (MM) and non-Hodgkin lymphoma (NHL), the first prospective randomized trial compared the safety and efficacy of tbo-filgrastim in combination with plerixafor with that of filgrastim in combination with plerixafor. This study found the tbo-filgrastim and filgrastim arms similar in all secondary endpoints. As compared to reference filgrastim when used for stem cell mobilization in patients with MM and NHL, tbo-filgrastim was not inferior in efficacy and had a similar safety. Results suggested the safe use of Granix instead of Neupogen for stem cell collection in patients undergoing autologous hematopoietic stem cell transplantation (auto-HSCT) for MM or NHL.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries